We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Dan Roden

Dan M Roden MD

Assistant Vice Chancellor for Personalized Medicine Professor of Medicine William Stokes Chair in Experimental Therapeutics Professor of Pharmacology

Dan Roden was born and raised in Montreal, and received his medical degree and training in Internal Medicine from McGill University.  He then went to Vanderbilt where he trained in Clinical Pharmacology and Cardiology, and has been a faculty member there since. His initial career focus – that he has maintained – was studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies.  Over the last 10 years, Dr. Roden has led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation.  He directs the Vanderbilt DNA databank BioVU, and is one of the key leaders overseeing the Vanderbilt PREDICT project that is preemptively embedding pharmacogenomic variant data in the Vanderbilt electronic medical record.

Dr. Roden served as Director of the Vanderbilt Arrhythmia Service, director of the Division of Clinical Pharmacology (1992-2004), and in 2006 was named Assistant Vice-Chancellor for Personalized Medicine.  Dr. Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics and the Distinguished Scientist Award and the Douglas Zipes lectureship from the Heart Rhythm Society.  He currently serves on the Science Board of the FDA. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.